DFS | OS | |||||
---|---|---|---|---|---|---|
HR | 95% CI | Wald’s p | HR | 95% CI | Wald’s p | |
alphaB-crystallin * Treatment | 0.72 | 0.75 | ||||
alphaB-crystallin neg vs. pos in non-paclitaxel treated | 1.21 | 0.48-3.01 | 0.88 | 0.35-2.23 | ||
alphaB-crystallin neg vs. pos in paclitaxel treated | 0.81 | 0.53-1.24 | 0.60 | 0.38-0.97 | ||
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin neg | 1.23 | 0.92-1.63 | 1.35 | 0.97-1.86 | ||
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin pos | 0.82 | 0.31-2.17 | 0.93 | 0.35-2.47 | ||
BRCA1 * Treatment | 0.55 | 0.99 | ||||
BRCA1 neg vs. pos in non-paclitaxel treated | 1.43 | 0.34-5.91 | 1.01 | 0.24-4.20 | ||
BRCA1 neg vs. pos in paclitaxel treated | 0.96 | 0.61-1.49 | 1.02 | 0.59-1.77 | ||
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 neg | 1.19 | 0.90-1.58 | 1.29 | 0.94-1.78 | ||
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 pos | 0.79 | 0.18-3.43 | 1.31 | 0.29-5.85 | ||
BRCA1 * Treatment | 0.37 | 0.48 | ||||
BRCA1 WT vs. mut in non-paclitaxel treated1 | . | . | . | . | ||
BRCA1 WT vs. mut in paclitaxel treated | 0.61 | 0.21-1.76 | 0.64 | 0.19-2.17 | ||
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 WT | 0.76 | 0.25-2.25 | 0.29 | 0.06-1.37 | ||
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 mut1 | . | . | . | . | ||
p53 * Treatment | 0.35 | 0.58 | ||||
p53 neg vs. pos in non-paclitaxel treated | 1.06 | 0.61-1.84 | 0.94 | 0.50-1.78 | ||
p53 neg vs. pos in paclitaxel treated | 0.80 | 0.63-1.02 | 0.77 | 0.58-1.03 | ||
Non-paclitaxel treated vs. paclitaxel treated in p53 neg | 1.36 | 0.82-2.23 | 1.37 | 0.76-2.47 | ||
Non-paclitaxel treated vs. paclitaxel treated in p53 pos | 1.02 | 0.72-1.43 | 1.13 | 0.77-1.65 |